What They Build
MedGenome operates a CAP-accredited, NGS-enabled genetic testing laboratory and research platform across oncology, rare and inherited diseases, reproductive health, infectious disease, and preventive wellness.
Why They Matter
Genomics becomes clinically useful only when it is attached to decisions, not just sequencing machines. MedGenome matters because it has built a large genetic testing network across India's healthcare system while also serving research and pharmaceutical customers. The question is how deeply precision medicine roots into routine treatment decisions.
Founders
Sam Santhosh
Recent Milestones
- Founded in 2013 by Sam Santhosh as a spin-off from SciGenom Labs
- Portfolio expanded to 1,300-plus genetic tests
- Network disclosed across 18,000-plus clinicians and 6,000-plus hospitals
- $55M Series D closed in 2020, led by LeapFrog Investments
- $47.5M Series E closed in July 2025, co-led by Maj Invest and Novo Holdings
- Total capital raised disclosed at about $264M across 10 funding rounds
- Expansion into multi-omics research services and integrated diagnostics underway